To contextualize results from the single-arm ELM-2 study of odronextamab (CD20 × CD3 bispecific antibody) in relapsed/refractory (R/R) follicular lymphoma (FL) (N = 128), a post-hoc comparison was conducted versus third-line or later systemic therapies used in the real world (3L + RWST) in FLORA, a multinational, noninterventional study (N = 83; 100 lines of therapy). After weighting, objective response rate (80.5 vs. 52.7%; odds ratio OR, 3.75 95% CI, 1.98-7.11), complete response rate (73.4 vs. 33.6%; OR, 5.39 95% CI, 2.76-10.53), median (months) progression-free survival (20.7 vs. 11.5; hazard ratio HR, 0.76 95% CI, 0.46-1.24), event-free survival (19.5 vs. 7.6; HR, 0.52 95% CI, 0.36-0.77), overall survival (not reached vs. 26.2; HR, 0.60 95% CI, 0.37-0.97), and time to next treatment or death (40.4 vs. 9.7; HR, 0.49 95% CI, 0.33-0.72) favored odronextamab versus 3L + RWST. Despite FLORA's limited sample size, these data further support odronextamab monotherapy for 3L + R/R FL.
Bachy et al. (Tue,) studied this question.